Grant: Discovery Grants Program - Individual
University of British Columbia
$40,000.00
Bioprocess Engineering of Mammalian Cell Culture
EF 2016-17
Résumé
Mammalian cell cultures have become the dominant technology for the production of biological therapeutics. These cultures are also increasingly used for the research and development of novel immunotherapies and stem cell therapies, used to treat injuries and chronic diseases. The great promise of these emerging treatments comes with great challenges, many of those in the field of cell culture process engineering.
The long-term goal of this program is to enable safer and more economical manufacture of mammalian cell products. This will be achieved by recently developed technologies to perform novel research that will increase the understanding of cell culture processes. We should thereby contribute both to accelerated process development as well more effectively optimized bioprocesses. This will include work in the relatively simple context of mammalian cell protein manufacturing, as well as the more complex analysis of therapeutic cell cultures. In particular, improved process analytical technologies will be developed to greatly increase the high-throughput analysis of mammalian cell culture populations and accelerate the selection of specific cells that are most suitable for manufacturing.
The development of reliable and economical means of mammalian cell manufacturing is essential to ensure that many promising emerging health care technologies actually become widely available to the patients who need them. Ultimately, increased access to safe and affordable cell culture products will improve the quality of many thousands of Canadian lives. UBC and Canadian multidisciplinary groups are among the leaders in this area of research. Exporting these technologies and knowledge should benefit populations around the world as well as translate into substantial commercial benefits for Canadians.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2015-03736
Name nom
Piret, James
Department département
Michael Smith Laboratories - Michael Smith Laboratories
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
2
Nb partie
5
Application title
Bioprocess Engineering of Mammalian Cell Culture
Keyword
NSERC
Application summary
Mammalian cell cultures have become the dominant technology for the production of biological therapeutics. These cultures are also increasingly used for the research and development of novel immunotherapies and stem cell therapies, used to treat injuries and chronic diseases. The great promise of these emerging treatments comes with great challenges, many of those in the field of cell culture process engineering.
The long-term goal of this program is to enable safer and more economical manufacture of mammalian cell products. This will be achieved by recently developed technologies to perform novel research that will increase the understanding of cell culture processes. We should thereby contribute both to accelerated process development as well more effectively optimized bioprocesses. This will include work in the relatively simple context of mammalian cell protein manufacturing, as well as the more complex analysis of therapeutic cell cultures. In particular, improved process analytical technologies will be developed to greatly increase the high-throughput analysis of mammalian cell culture populations and accelerate the selection of specific cells that are most suitable for manufacturing.
The development of reliable and economical means of mammalian cell manufacturing is essential to ensure that many promising emerging health care technologies actually become widely available to the patients who need them. Ultimately, increased access to safe and affordable cell culture products will improve the quality of many thousands of Canadian lives. UBC and Canadian multidisciplinary groups are among the leaders in this area of research. Exporting these technologies and knowledge should benefit populations around the world as well as translate into substantial commercial benefits for Canadians.